Luminus Management’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-370,969
Closed -$404K 27
2025
Q4
$404K Sell
370,969
-541,836
-59% -$606K 0.35% 17
2025
Q3
$922K Buy
912,805
+117,975
+15% +$129K 0.83% 13
2025
Q2
$914K Buy
794,830
+338,186
+74% +$437K 0.24% 14
2025
Q1
$680K Sell
456,644
-560,076
-55% -$672K 0.22% 17
2024
Q4
$832K Sell
1,016,720
-136,195
-12% -$120K 0.96% 12
2024
Q3
$940K Buy
1,152,915
+427,090
+59% +$350K 0.48% 18
2024
Q2
$595K Buy
725,825
+8,168
+1% +$6.92K 0.34% 20
2024
Q1
$581K Sell
717,657
-55,589
-7% -$72.1K 0.26% 18
2023
Q4
$1.09M Sell
773,246
-101,854
-12% -$134K 0.3% 20
2023
Q3
$1.02M Sell
875,100
-3,278
-0.4% -$4.75K 0.32% 22
2023
Q2
$1.22M Buy
878,378
+23,078
+3% +$34.8K 0.37% 20
2023
Q1
$1.2M Buy
855,300
+30,300
+4% +$42K 0.29% 24
2022
Q4
$1.12M Sell
825,000
-21,662
-3% -$39K 0.28% 18
2022
Q3
$1.29M Sell
846,662
-27,142
-3% -$67.5K 0.45% 20
2022
Q2
$1.98M Buy
873,804
+118,322
+16% +$263K 0.61% 16
2022
Q1
$2.54M Sell
755,482
-502,582
-40% -$1.84M 0.57% 11
2021
Q4
$6.76M Buy
+1,258,064
New +$10.2M 1.59% 12

Other funds holding LUCD

Luminus Management's LUCD Position: Q1 2026 in Review

Luminus Management sold out of Lucid Diagnostics (LUCD) in Q1 2026, closing a stake of 370,969 shares — an estimated $404K sold.

Luminus Management first reported a position in LUCD in Q4 2021 and held it in 17 quarters. The position peaked at $6.76M in Q4 2021. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Luminus Management reported no remaining Lucid Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Luminus Management sold 370,969 Lucid Diagnostics shares in Q1 2026, an estimated $404K.
  • Luminus Management first reported a position in Lucid Diagnostics in Q4 2021 and held it in 17 quarters.
  • Luminus Management's Lucid Diagnostics position peaked at $6.76M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Luminus Management's 13F filing for Q1 2026, filed 15 May 2026.